Literature DB >> 3814921

Effects of morphine on catecholamine release and arrhythmias evoked by myocardial ischaemia in rats.

K Addicks, H Hirche, F M McDonald, W Polwin.   

Abstract

The effects of morphine (10 mg kg-1 i.p.) on haemodynamics, arrhythmias and plasma and myocardial catecholamines (CA) were studied after coronary artery occlusion in anaesthetized rats. Myocardial intraneuronal CA were assessed histofluorimetrically and CA concentrations measured by high performance liquid chromatography. Morphine increased blood pressure, presumably due to higher plasma noradrenaline (NA) concentrations found in morphine-treated rats. Morphine increased the area of catecholamine-containing fluorescing neurones in the myocardium (as a percentage of total field area) 60 min after sham-operation (0.87 +/- 0.07%) or occlusion (0.57 +/- 0.05%) compared to untreated animals (0.67 +/- 0.06 and 0.38 +/- 0.03% respectively). Tissue NA content was not significantly affected by coronary occlusion and/or morphine within the first 60 min. Morphine had no effect on ischaemia-induced arrhythmias. Whether the higher intraneuronal NA content following morphine resulted from reduced central sympathetic outflow to the heart, presynaptic inhibition of NA release, or increased uptake due to higher plasma concentrations is unclear. Ischaemia-induced local NA release appears independent of these mechanisms, as it was unaffected by morphine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3814921      PMCID: PMC1917263          DOI: 10.1111/j.1476-5381.1987.tb16846.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  The role of neural input in the effects of morphine on the rat adrenal medulla.

Authors:  T R Anderson; T A Slotkin
Journal:  Biochem Pharmacol       Date:  1976-05-01       Impact factor: 5.858

Review 2.  Regulation of noradrenaline release by presynaptic receptor systems.

Authors:  K Starke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1977       Impact factor: 5.545

3.  Thyroid function and the cardiac disposition of catecholamines.

Authors:  R J WURTMAN; I J KOPIN; J AXELROD
Journal:  Endocrinology       Date:  1963-07       Impact factor: 4.736

4.  Influence of sympathetic tone on ventricular fibrillation threshold during experimental coronary occlusion.

Authors:  B R Kliks; M J Burgess; J A Abildskov
Journal:  Am J Cardiol       Date:  1975-07       Impact factor: 2.778

Review 5.  Biochemical aspects of arrhythmogenesis and ventricular fibrillation.

Authors:  L H Opie; D Nathan; W F Lubbe
Journal:  Am J Cardiol       Date:  1979-01       Impact factor: 2.778

6.  Comparative effects of morphine, meperidine and pentazocine on cardiocirculatory dynamics in patients with acute myocardial infarction.

Authors:  G Lee; A N DeMaria; E A Amsterdam; F Realyvasquez; J Angel; S Morrison; D T Mason
Journal:  Am J Med       Date:  1976-06       Impact factor: 4.965

7.  A prospective random comparison of halothane and morphine for open-heart anesthesia: one year's experience.

Authors:  T J Conahan; A J Ominsky; H Wollman; R A Stroth
Journal:  Anesthesiology       Date:  1973-06       Impact factor: 7.892

8.  Changes in norepinephrine stores in the canine heart following experimental myocardial infarction.

Authors:  P Mathes; S Gudbjarnason
Journal:  Am Heart J       Date:  1971-02       Impact factor: 4.749

9.  Neural activity and ventricular fibrillation.

Authors:  B Lown; R L Verrier
Journal:  N Engl J Med       Date:  1976-05-20       Impact factor: 91.245

10.  Central cardiovascular effects of morphinomimetic peptides in dogs.

Authors:  M Laubie; H Schmitt; M Vincent; G Remond
Journal:  Eur J Pharmacol       Date:  1977-11-01       Impact factor: 4.432

View more
  1 in total

1.  Ventricular noradrenaline concentrations in naïve and morphine-treated rats subjected to acute myocardial ischaemia.

Authors:  W W Ko; S Dai; M Y Chan
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.